MorphoSys: That Celgene-abandoned cancer drug isn't dead yet

Germany's MorphoSys is moving on after the surprise cancelation of a Celgene partnership spooked investors and battered the company's share price, with CEO Simon Moroney preaching patience for an early-stage cancer candidate.

Juno and Novartis settle CAR-T patent fight with little fanfare

Novartis and Juno Therapeutics, pioneers in a promising new field of cancer treatment, have reached a settlement in their long-running patent dispute, clearing the way for each to advance rival therapies designed to weaponize the immune system.

Bristol-Myers bets big on gene therapy with a $1B uniQure deal

Bristol-Myers Squibb is the latest pharma heavyweight to buy into gene therapy's renaissance, signing a deal with uniQure worth as much as $1 billion and getting its hands a novel cardiovascular treatment.

UPDATED: GlaxoSmithKline to create new vaccines hub, uprooting R&D groups in Cambridge, Philly

GlaxoSmithKline is setting up a global vaccines hub in Rockville, MD, in the wake of its big asset swap with Novartis. And the move will force hundreds of staffers in Cambridge, MA, and Philadelphia to either look for a relocation package or exit the company.

23andMe poaches another Genentech vet as it delves into biotech

23andMe, the Silicon Valley maker of personalized gene tests, has picked off another Genentech luminary to help it evolve into a biotech company, recruiting the famed drugmaker's head of bioinformatics.

AstraZeneca razes R&D facilities in Delaware

AstraZeneca's former R&D operations in Delaware, abandoned years ago in the pharma giant's ongoing restructuring and downsizing, are being razed.

Ipsen barrels into Boston with a new R&D hub and a Harvard pact

French drugmaker Ipsen is the latest global giant turning to the Boston area for a leg up in R&D, cutting the ribbon on a Cambridge research center and breaking it in by signing a deal with Harvard University.

Novartis steps in to help bankroll CRISPR-Cas9 pioneer Caribou

Pharma heavyweight Novartis has stepped in to help bankroll Berkeley, CA-based Caribou Biosciences, one of the upstart leaders in the race to develop the cutting-edge CRISPR-Cas9 gene editing technology.

Sanofi adds a $120M computational drug design deal with Schrödinger

Looking to gain an edge for its lackluster in-house R&D operations, Sanofi has signed on with Schrödinger to use computational design technology to help guide up to 10 drug discovery programs, promising to pay up to $120 million in milestones for the work.

Index Ventures banks €650M for its new tech fund

Index Ventures now has 650 million more euros to invest. The venture group, which has two big teams active on both sides of the Atlantic in life sciences as well as tech, filed documents with the SEC noting that its new Index Ventures Growth III--domiciled in Jersey--is fully sold.

PureTech's heavyweight contender Gelesis swings for a $60M IPO

With its stomach-filling particles now in a pivotal study in Europe for obesity, Boston-based Gelesis has thrown its hat into the crowded biotech IPO ring, looking to raise $60 million from an investment community that has yet to lose its appetite for biotech stocks.

Parisian IPO boomlet marches on, Cardio3 rides CAR-T to Wall Street, PhII flop smacks Can-Fite

In this week's EuroBiotech Report, Cerenis Therapeutics and Ose Pharma both debuted on the Paris stock exchange. And with Sensorion filing the paperwork for a €12 million ($12.9 million) listing, Paris is set move within touching distance of its 2014 IPO haul before the daffodils in the Jardin des Tuileries finish blooming. And more.

Fast-track approvals gain traction in Europe as EMA, U.K. schemes take off

The European Medicines Agency (EMA) is preparing to step up its conditional approval initiative to cut the time and data needed to bring new drugs to patients. Having received applications to enter 58 drugs into the program, EMA has selected a treatment based on genes, cells or tissue engineering as the first candidate to advance to the next stage.

Sarepta CEO Chris Garabedian resigns

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Yale team says failed AstraZeneca drug shows promise in Alzheimer's

AstraZeneca's AZD0530 proved a disappointment as a new drug for solid tumors, but a Yale team says it may prove more effective in a new program for Alzheimer's.

Calico sheds light on its R&D mission with UCSF partnership

Google's secretive Calico signed yet another partnership with a world-class research outfit, this time divulging some details that could provide clues on how it plans to attack aging.

Prepping for a Duchenne study, Catabasis banks $12.4M in new fundraising

Cambridge, MA-based Catabasis is once again raising cash. According to a Form D filed with the SEC yesterday, the biotech has raised $12.4 million out of a $20.4 million raise.

VC heavyweights back a $150M NYC biotech fund with Lilly and Celgene in tow

New York City's nascent biotech investment fund is ready to get rolling, recruiting some venture capital partners to join Eli Lilly, Celgene and GE Ventures with hopes of pouring $150 million into the local life sciences startup scene.

Roche CEO Schwan flags more biopharma partnering ahead

Back at the big JP Morgan conference in San Francisco in January, Roche's big $1 billion-plus tie-up with Foundation Medicine made it clear to the most casual biopharma observer that the pharma giant plans to partner more frequently as it builds up its pipeline and expands on its diagnostics business.

Cardio3 pitches its stem cell, CAR-T pipeline to U.S. investors

Cardio3 Biosciences is set to become the latest European biotech to pitch up on Wall Street in search of cash from public investors. And with a clinical-phase CAR-T asset in its pipeline, the Belgian biotech stands a chance of tapping into investor enthusiasm for the red-hot niche.